{"entity":{"id":"nct03930953","kind":"trial","name":"A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory No","aka":[],"tldr":"A phase 1/2 trial of Golcadomide, Rituximab, Obinutuzumab in non-hodgkin lymphoma, run by Celgene, active and no longer recruiting.","summary":"A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) is a phase 1/2 interventional study registered as NCT03930953 by Celgene, with 438 participants planned, started 2019-05-20 and due to reach its primary completion in 2027-04-07. Interventions recorded: CC-99282, Rituximab, Obinutuzumab, Tafasitamab, Valemetostat. Conditions listed: Lymphoma, Non-Hodgkin. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03930953","url":"https://clinicaltrials.gov/study/NCT03930953"}],"tags":["ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["golcadomide","rituximab","obinutuzumab","tafasitamab"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03930953","phase":"1/2","setting":"A Phase 1/2, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination With Anti-Lymphoma Agents in Subjects With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL).","sponsor":"Celgene","participation":[{"nct":"NCT03930953","source":"https://clinicaltrials.gov/study/NCT03930953","fetchedAt":"2026-10-07T16:53:11.482Z","studySha256":"f64f006ca44ca292f9cc73967222e3936e45b2a6bd7184b2973e40e2541ad580","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-02-19","leadSponsor":"Celgene","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":438,"enrolmentType":"ESTIMATED","siteCount":66,"recruitingSiteCount":0,"countries":["Argentina","Austria","Belgium","Brazil","Canada","Chile","China","Denmark","France","Israel","Italy","South Korea","Spain","United Kingdom","United States"]}],"started":"2019-05-20","startedType":"actual","enrolled":438,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03930953/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"golcadomide","kind":"drug","name":"Golcadomide","route":"/drugs/golcadomide/"},{"id":"obinutuzumab","kind":"drug","name":"Obinutuzumab","route":"/drugs/obinutuzumab/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"},{"id":"tafasitamab","kind":"drug","name":"Tafasitamab","route":"/drugs/tafasitamab/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}